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A B S T R A C T
Purpose: Determining optimal b-value pair for differentiation between normal and prostate cancer (PCa) tissues. Methods: Forty-
three patients with diagnosis or PCa symptoms were included. Apparent diffusion coefficient (ADC) was estimated using 
minimum and maximum b-values of 0, 50, 100, 150, 200, 500 s/mm2 and 500, 800, 1100, 1400, 1700 and 2000s/mm2, 
respectively. Diagnostic performances were evaluated when Area-under-the-curve (AUC) > 95%.
Results: 15 of the 35 b-values pair surpassed this AUC threshold. The pair (50, 2000 s/mm2) provided the highest AUC (96%) 
with ADC cutoff 0.89 × 10–3 mm2/s, sensitivity 95.5%, specificity 93.2% and accuracy 94.4%
Introduction
Diagnosing prostate disease is a complex task and typically requires
a combination of clinical, biochemical and imaging biomarkers [1,2].
Specifically, the diagnosis of prostate cancer (PCa) is based on clinical
symptoms, digital rectal examination, prostate specific antigen (PSA)
levels, transrectal ultrasonography (TRUS) and tissue sample biopsy
guided by TRUS, from which histopathological tissues are graded using
the Gleason Score (GS). Despite advances in these techniques, the ac-
curacy of the tests remains limited, missing some PCa cases [3].
Multi-parametric magnetic resonance imaging (MP-MRI) can aid in
the detection and characterization of PCa combining anatomical,
functional and molecular imaging, providing improved support for
decision-making regarding clinical treatment [4,5]. This MP-MRI ap-
proach includes the use of diffusion-weighted imaging (DWI) for
studying the prostate. DWI provides qualitative and quantitative mi-
crostructural information, in a non-invasive manner, making use of
water diffusion to probe prostatic tissue [6]. DWI measures the motion
of water molecules within tissues, which is influenced by the presence
of intra and extracellular compartments as well as intravascular spaces.
The apparent diffusion coefficient (ADC) is a measure of water mobility
and can be estimated from the signal intensity (SI) decay between two
or more images exhibiting different levels of diffusion contrast (quan-
tified by the b-value). Previous studies reported reduced ADC values in
PCa compared to benign and healthy tissue [7,8]. In order for ADC
quantification to become more widespread in the clinic, it is essential to
standardize prostate DWI protocols. Several parameters influence both
the acquisition time and the measured ADC values, impacting the ac-
curacy of the technique; these include the repetition time (TR), the echo
time (TE) and the number and the choice of b-values [7,9–11].
T
To minimize scanning time, while maintaining the best possible
diagnostic performance, the determination of an optimal pair of b-va-
lues is desirable. Choosing the maximum and minimum b-values for
adequate ADC estimation thus becomes critical. Recent recommenda-
tions state that the minimum b-value should range between 50 and
100 s/mm2, to reduce the impact of micro-perfusion in capillaries on
the ADC estimate, while the maximum b-value should be chosen within
the 800–1000 s/mm2 interval [12]. However, it has been acknowledged
that visual evaluation of DWI acquired with b-values higher than
1400 s/mm2 can be advantageous due to improved lesion conspicuity
[12]. Several studies have already explored pairs of b-values with
maximum b-values beyond this limit for ADC quantification
[7,8,10,11,13]. However, there is still no consensus regarding the op-
timal b-value pair at 3 T. A study by Wang et al. [11] at 3.0 T compared
diagnostic performance for different maximum b-values, but selected a
fixed minimum b-value of 0 s/mm2, which is not in agreement with
current guidelines [12].
At 1.5 T, Peng et al. [10] compared seven b-value pairs ranging from
0 to 2000 s/mm2 obtaining an ADC cut-off of 1.44 × 10−3 mm2/s,
with the highest sensitivity (86.2%) and specificity (92.3%) for the b-
value pair 0, 1000 s/mm2. However, since the signal-to-noise ratio
(SNR) of the images is dependent on the field strength, the role of
higher b-values for ADC quantification needs to be reevaluated at 3 T.
The purpose of this study was therefore to evaluate the optimal pair
of b-values for ADC estimation at 3.0 T, resulting in the best perfor-
mance for differentiating healthy tissue from PCa.
Methods
Subjects and lesions
This prospective study was approved by the Hospital Ethics
Committee (reference number 251/12(190-DEFI/195-CES)), and all
patients gave written informed consent.
One-hundred consecutive male patients, referred to our institution
from October 2013 to January 2015, with previous diagnosis or
symptoms suggestive of PCa and clinical indication to perform pelvic
MRI, were enrolled in the study. Exclusion criteria were: a) prior sur-
gery, hormonal or radiation therapy before MP-MRI (n= 11); b) MP-
MRI analysis without detected lesions (n= 19); c) absence of positive
histological PCa results obtained up to 6 months from MRI examination
(n= 24); and d) diffusion images with artifacts (n= 3). The final
number of patients was reduced to 43 (average age of 63, age range:
45–76 years old). The pathologic confirmation of PCa was made by
TRUS biopsy (n= 21) or prostatectomy (n= 22).
MR equipment and image acquisition protocol
Prostate MP-MRI was done using a 3 T MR scanner (Achieva TX
with Multi Transmit technology, Philips Healthcare, Netherlands)
equipped with a 32 channel phased-array coil. The MRI protocol in-
cluded: T2-weighted (w) turbo spin-echo (TSE) sequence in the axial
and coronal planes TR, 4000 ms; TE, 100 ms; thickness, 3 mm; matrix,
200 × 200; number of excitations (NEX) 2; scan time 1:12 min); sa-
gittal T2-w TSE sequence (TR, 4000 ms; TE, 140 ms; thickness, 3.5 mm;
matrix, 232 × 200; NEX 2; scan time 1:12 min); axial T1-w TSE se-
quence (TR, 589 ms; TE, 20 ms; thickness, 3.5 mm; matrix, 316 × 269;
NEX 2; scan time 2:12 min); axial T2-w TSE sequence (TR, 4722 ms; TE,
140 ms; thickness, 3.5 mm; matrix, 432 × 400; NEX 2; scan time
2:40 min) with spectral pre-saturation with inversion recovery (SPIR);
dynamic axial T1-w contrast-enhanced fast field echo (CE-FFE-T1) with
fat saturation (TR, 6.4 ms; TE, 3.2 ms; thickness, 3 mm; matrix,
160 × 160; NEX 3; scan time 2:39 min). DWI was acquired before the
dynamic sequence with a single-shot spin-echo echo-planar imaging
(SS-SE-EPI) sequence with SPIR for fat suppression and parallel ima-
ging. Sensitizing diffusion gradients were applied in the -x, -y and -z
directions to generate 3-scan trace images with b-values of 0, 50, 100,
150, 200, 500, 800, 1100, 1400, 1700 and 2000 s/mm2 (slice thickness
6 mm; TR 3258 ms; TE, 66 ms, matrix, 124 × 100, field-of-view
375 × 375 mm2; NEX 2; scan time 13:21 min).
Data analysis
Prostate images were evaluated by a radiologist (with> 5 years of
experience) who localized and described the lesions combining in-
formation from morphologic and dynamic images.
Taking into account the clinical imaging report, two radiology re-
searchers, with training in DWI (both with over 5 years of experience),
localized the lesions in the DW images. T1-w and T2-w images were
evaluated to avoid areas of post-biopsy hemorrhage and ADC maps
were generated to rule out T2-w shine-through effects. The slice that
better depicted the lesion, corresponding to its highest dimension was
chosen, accounting for the prostate sector identified by the prosta-
tectomy or TRUS biopsy report.
Regions of interest (ROI) were drawn around the lesion encom-
passing the hyperintense region at b = 2000 s/mm2 and copied to the
other diffusion images. Regarding healthy glandular tissue, ROI were
drawn in T2-w images with a fixed size of 21.75 mm2 in the peripheral
zone (PZ) and in the central gland (CG) and copied to the DW images.
These images were then visualized so as to ensure that the ROI fell
within the intended anatomical structure and did not exhibit hyper-
intense signal in b2000 s/mm2. Furthermore, to avoid MRI-occult le-
sions, the histology reports were taken into account when delineating
the ROI. Mean signal intensities (SI) for each DW image were recorded
for both regions of healthy tissue and lesions.
ADC maps were generated for each b-value combination using the
software Osirix Dicom Viewer version 5.6.1. with the equation [14]:
= − −ADC SI SI b bln( ) ( 2 1)b b2 1
where SIb2 is the SI corresponding to the higher b-value b2, and SIb1
corresponded to the lower b-value b1.
The ADC was estimated using different combinations of minimum b-
values of 0, 50, 100, 150, 200, 500 s/mm2 and maximum b-values of
500, 800, 1100, 1400, 1700 and 2000 s/mm2, resulting in thirty five
studied b-value combinations (e.g. 0, 800; 0, 2000; 50, 1000; 100,
2000 s/mm2 and so forth). The b-value combination 500,500 s/mm2
was ruled out.
Statistical analysis and clinical validation
A descriptive analysis was performed for normal tissue and PCa. For
each b-value combination, mean ADC values and standard deviations
(SD) were computed for healthy tissue and malignant lesions.
For all the 35 b-value combinations, the area-under-the-curve (AUC)
was estimated by receiver operating characteristics (ROC) analysis. The
best pairs of b-values were identified as the combinations that showed
AUC> 95%. The pairs of b-values that did not fulfill this criterion were
excluded. For the best b-value pairs, ADC cut-off and diagnostic per-
formance were calculated considering Youden statistics and the
minimum distance between the ROC curve and the ideal point of co-
ordinates (0, 1). AUC comparison for obtained ROC curves was done
according to Delong et al. using MedCalc software version 17 (Medcalc
Software, Ostend, Belgium) [15].
The Mann-Whitney test was used to evaluate differences between
PCa and normal tissue, both globally and by region of lesion localiza-
tion, for the best b-value combinations.
Overall differences in mean ADC values between the best b-value
pairs were assessed, using the Friedman nonparametric repeated mea-
sures analysis of variance test.
The Statistical Package for the Social Sciences (SPSS) software
version 20.0 was used for analysis and a p-value< 0.05 was considered
statistically significant.
Results
Subject and lesion characterization
The final sample included 43 patients diagnosed with PCa.
Median ± interquartile range PSA values were 7.0 ± 4.2 ng/dL. The
median ± interquartile range area of the 43 lesions was 14 ± 7 mm2.
Thirty-five lesions were localized in the PZ, 5 in the CG and 3 involved
both regions. Of the 43 lesions, 7 had a GS 3 + 3, 13 GS 3 + 4, 15 GS
4 + 3, 4 GS 4 + 4 and 4 GS 4 + 5. In the CG portion, 3 lesions were
classified as GS 3 + 3, 1 GS 3 + 4 and 1 GS 4 + 4. In the PZ, lesions
were classified as: 4 GS 3 + 3, 12 GS 3 + 4, 12 GS 4 + 3, 3 GS 4 + 4
and 4 GS 4 + 5. Three lesions localized between the 2 different zones
were classified as GS 4 + 3. For 22 lesions, histological results were
performed by prostatectomy (2 in the CG, 19 in the PZ and 1 in both
areas). For the other 21 lesions histology was obtained from TRUS
biopsy.
Fig. 1 illustrates a case of a 65-years-old patient with PCa and in-
cludes different types of images: T2-w (Fig.1a), DWI with a b-value of
50 s/mm2 (Fig.1b), b-value of 2000 s/mm2 (Fig.1c) and the corre-
sponding ADC map (Fig.1d).
ADC values by tissue type
Mean ADC ranges for all prostate tissues in the different localiza-
tions are summarized in Table 1, considering the 35 b-value pairs stu-
died.
For the combinations that included a minimum b-value of 0 s/mm2,
absolute ranges of mean ADC were higher for all the tissues, compared
to when a higher minimum b-value was used.
Also, maximum b-values seemed to influence the range of ADC
values. When maximum b-values increased, the range of absolute mean
ADC values tended to decrease for all tissue types.
Diagnostic performance and mean ADC values
For all the 35 b-value combinations, AUC ranged from
90.0%–96.0%. For the best 15 b-value combinations having
AUC> 95%, the ADC cut-offs and diagnostic performance in lesion
discrimination are presented in Table 2.
The AUC ranged from 95.1% to 96% to separate PCa from normal
tissue. The comparison between ROC curves showed no significant
differences in AUC between the best b-value pairs (p > 0.05). In any
case, from the best combinations, the b-value pair 50, 2000 s/mm2
showed the highest AUC (96.0%). Using an ADC cut-off of
0.89 × 10−3 mm2/s sensitivity, specificity and accuracy were 95.5%,
93.2% and 94.4%, respectively. Fig. 2 presents the ADC distribution for
normal (including peripheral zone and central gland) and malignant
tissue for the b-value combination 50, 2000 s/mm2 and corresponding
ADC cut-off value used to separate PCa from normal tissue.
A detailed analysis of ADC values for normal tissue by region and
PCa lesion localization for the 15 best b-value pair combinations is
shown in Table 3. For all b-value combinations, mean ADC values
showed significant differences between normal tissue and PCa globally
(p < 0.001), in the PZ region (p < 0.001) and in the CG region
(p < 0.001).
According to the performed Friedman test, mean ADC values for
PCa and normal tissue were significantly different between the best b-
Fig. 1. A 65-years-old patient with PCa in the left PZ of the 
prostate. (a) T2-w image shows a hipointense signal area in 
the left PZ. (b) DW image with a b-value of 50 s/mm2. (c) 
DW image with a b-value of 2000 s/mm2 showing a hy-
perintense signal area corresponding to the tumor. (d) The 
corresponding ADC map estimated from b = 50, 2000 s/
mm2 shows a hypointense area, confirming the presence of 
the lesion. Mean ADC in the lesion was 0.68 × 10−3 mm2/
s.
value pairs (p < 0.001), showing that the used b-values influence
mean ADC results.
Discussion
The choice of b-values included in the DWI sequence is a central
research issue, since it impacts the estimated ADC values [8,13,16,17].
Prostate studies focusing on specifically investigating the best b-value
pair for ADC quantification at 3.0 T are still scarce [8,11,13,18]. Pre-
vious studies reported mean ADC values ranging from
0.65–1.15 × 10−3 mm2/s in PCa and 0.96–1.79 × 10−3 mm2/s for
normal tissue [8,11,13,18]. In our study, globally, mean ADC values for
PCa ranged from 0.56–1.32 × 10−3 mm2/s and between 0.81 and
1.74 × 10−3 mm2/s for normal tissue. Compared to the previously
mentioned studies, our mean ADC ranges were similar for both PCa and
normal tissue, although the observed ranges were slightly wider for
both tissue types. Different factors could explain the difference in the
mean ADC ranges between studies, namely variations in the physiolo-
gical characteristics of the studied tissue types and localization of the
lesions, PCa GS classification, differences in DWI protocols, including
the choice of b-values and the methodology used in image analysis.
Our results demonstrate that PCa and normal tissue ADC values vary
substantially with b-value combinations, in agreement with other stu-
dies. Previous ADC quantification studies used maximum b-values from
400 to 1000 s/mm2 combined with b = 0 s/mm2, reporting ADC in PCa
between 0.71 and 1.87 × 10−3 mm2/s and 1.03–3.71 × 10−3 mm2/s
in healthy tissue [8,13,16,17,19–21]. In our study, for similar combi-
nations (maximum b-values between 500 and 1100 s/mm2 combined
with b = 0 s/mm2), the range of ADC values for PCa was equivalent
(1.01–1.32 × 10−3 mm2/s). However, for both areas of normal
glandular tissue (PZ and CG), the range and mean ADC values were
lower than those previously reported [8,13,16,17,19].
For maximum b-values between 1000 and 2000 s/mm2, combined
with b = 0 s/mm2, previous studies reported ADC values ranging from
0.65–0.88 × 10−3 mm2/s for PCa and 1.07–1.44 × 10−3 mm2/s for
healthy tissue [7,11,18]. Comparable ADC ranges were found in our
study for similar b-value combinations.
Other research groups used minimum b-values higher than b = 0 s/
mm2 and maximum b-values within 500–1000 s/mm2, reporting PCa
and normal tissue ADC ranging 0.79–1.5 × 10−3 mm2/s and
1.39–2.7 × 10−3 mm2/s, respectively. When testing similar b-value
combinations, our results were similar for PCa, ranging
0.76–1.16 × 10−3 mm2/s. However, in healthy tissue a lower max-
imum ADC value was obtained [22–24].
Overall, our results confirm that the estimated ADC is influenced by
the used b-values. Using a minimum b-value higher than 0 s/mm2 leads
to lower ADC values. This was expected since including b = 0 s/mm2
increases the contribution of micro-perfusion effects. This effect causes
Table 1
Summary of mean ADC ranges for normal and PCa tissues for the 35 b-value combinations studied globally and by prostate region.
b-value pairs (s/mm2) ADC in PCa
(×10−3 mm2/s)
ADC in Healthy tissue
(×10−3 mm2/s)
Global PZ CG Global PZ CG
All 35 studied combinations 0.56–1.32 0.56–1.33 0.53–1.26 0.81–1.74 0.81–1.89 0.80–1.74
bmin = 0 0.75–1.32 0.75–1.33 0.71–1.26 1.07–1.87 1.08–1.89 1.03–1.74
bmin > 0 0.56–1.16 0.56–1.17 0.53–1.08 0.81–1.68 0.81–1.70 0.80–1.55
bmax≤ 1100 0.76–1.32 0.77–1.32 0.70–1.26 1.15–1.87 1.16–1.89 1.08–1.74
bmin = 0;bmax≤ 1100 1.01–1.32 1.02–1.33 0.96–1.26 1.48–1.87 1.49–1.89 1.38–1.74
bmin > 0;bmax≤ 1100 0.76–1.16 0.77–1.17 0.70–1.08 1.15–1.68 1.16–1.70 1.08–1.55
bmax≥ 1100 0.56–1.01 0.56–1.02 0.53–0.96 0.81–1.48 0.81–1.49 0.80–1.38
bmin = 0;bmax≥ 1100 0.75–1.01 0.75–1.02 0.71–0.96 1.07–1.48 1.08–1.49 1.03–1.38
bmin > 0;bmax≥ 1100 0.56–0.93 0.56–0.94 0.53–0.86 0.81–1.38 0.81–1.39 0.80–1.28
bmin lowest b-value in the pair; bmax highest b-value in the pair; ADC apparent diffusion coefficient; CG central gland; PZ peripheral zone.
For example: bmin > 0;bmax≤ 1100 includes all the combinations for which bmin is higher than 0 s/mm2 and bmax is lower or equal to 1100 s/mm2.
Table 2
Best b-value pair combinations with AUC> 95%, respective ADC cut-offs and diagnostic
performance. The b-value combination with highest AUC is highlighted in bold.
Best b-value
combinations
(s/mm2)
AUC ADC cut-off
(×10−3 mm2/s)
Diagnostic performance (%)
Sensitivity Specificity Accuracy
50,800 95.1 1.28 88.6 90.9 89.8
150,800 95.1 1.21 86.4 90.9 88.7
50,1100 95.1 1.18 90.9 88.6 89.8
0,1400 95.2 1.11 86.4 90.9 88.7
50,1400 95.5 1.05 88.6 90.9 89.8
100,1400 95.1 1.02 86.4 90.9 88.7
150,1400 95.1 1.00 88.6 90.9 89.8
0,1700 95.4 1.00 88.6 90.9 89.8
50,1700 95.5 0.93 88.6 95.5 92.1
100,1700 95.1 0.92 88.6 90.9 89.8
0,2000 95.9 0.96 93.2 90.9 92.1
50,2000 96.0 0.89 95.5 93.2 94.4
100,2000 95.7 0.86 95.5 93.2 94.4
150,2000 95.5 0.82 90.9 90.9 90.9
200,2000 95.6 0.80 90.9 93.2 92.1
ADC Apparent diffusion coefficient, AUC Area under the curve.
Fig. 2. Box plots for ADC values (×10−3 mm2/s) for healthy and malignant tissue for the
combination of b = 50, 2000 s/mm2. The horizontal line represents the corresponding
ADC cut-off value for differentiating between normal and malignant tissues.
substantial signal attenuation at low b-values which explain higher ADC
values when including very low b-values [12]. Maximum b-values also
influence the ADC estimates; previous studies also showed that in-
creasing the maximum b-value leads to lower ADC values [25]. At
higher b-values the signal loss due to micro-perfusion effects is com-
pleted and only diffusion effects remain returning lower ADC values.
Moreover, at high b-values normal prostate tissue signal is suppressed,
increasing lesion conspicuity; the most malignant part of the tumor,
representing the region of highest restriction is highlighted, and lower
ADC values are measured. Higher b-values are nevertheless associated
with decreased SNR which could lead to underestimated ADC values
and lower diagnostic performances [26]. Despite this loss in SNR, in our
study the b-value pair with highest diagnostic performance was 50,
2000 s/mm2, even though there were no significant differences when
comparing the AUC between the 15 best b-value pairs. The combined
use of a 3 T equipment and a 32 channel receiver coil increase the
achievable SNR. This type of coil is not often available in the clinical
setting, where 4 to 16 channel coils are more frequently used
[7,8,11,13,17,18,21,24]. SNR is also influenced by the used TE and
guidelines recommend a TE lower than 90 ms [27] as used in our study
(TE 66 ms).
Another important issue under investigation is the number of b-
values used for ADC quantification. Multiple b-values can be used to
perform ADC measurements, impacting its accuracy and precision
[7,10,22]. Using a higher number of b-values increases the confidence
associated to the estimated ADC compared to when only two b-values
are used. Nevertheless, the larger the number of b-values included in a
DWI sequence, the longer its acquisition time. In our study, we chose to
evaluate only b-value pairs to identify the smallest set of b-values that
would enable accurate ADC quantification within the shortest possible
acquisition time, for wider applicability in the clinical practice.
The diagnostic performance of prostate DWI relies on the estab-
lished ADC cut-off. Our results were consistent with previous studies
[10,11] showing ADC values lower in malignant lesions than in normal
tissue and AUC ranging from 90% to 96% for all b-value pairs.
The b-value pair 50, 2000 s/mm2 showed the highest AUC (96%);
for an ADC cut-off of 0.89 × 10−3 mm2/s, sensitivity, specificity and
accuracy were 95.5%, 93.2% and 94.4%, respectively. Mean ADC va-
lues were 1.01 ± 0.14 (global), 1.02 ± 0.14 (PZ), 0.97 ± 0.12
(CG) × 10−3 mm2/s for normal tissue, and 0.69 ± 0.13 (global),
0.70 ± 0.14 (PZ) and 0.65 ± 0.1 (CG) × 10−3 mm2/s for PCa.
In a similar study at 1.5 T, Peng et al. used b-values of 0, 50, 200,
1500 and 2000 s/mm2 in 8 different b-value combinations, achieving
AUC between 88.0%–93.0%. The best AUC (93.0%) was achieved for
the b-value pair 0, 1000 s/mm2 and for the b-value pair 50, 2000 s/
mm2 AUC, sensitivity and specificity were 89%, 88.9% and 89.5%,
respectively. In their study, AUC comparison also showed no differ-
ences between the best b-value combinations [10]. Comparing our re-
sults to theirs, for a similar b-value pair (0,1100 s/mm2), a higher AUC
(94.7%) was obtained. In addition, in our study, higher AUC (96% vs
89%), sensitivity (95.5% vs 88.9%) and specificity (93.2% vs 89.5%)
were achieved when the b-value pair 50, 2000 s/mm2 was used for ADC
estimation. The differences found between studies could be due to a
higher SNR available at 3.0 T and to the use of a 32 channel phased-
array coil. According to Shah et al., the endorectal coils normally used
at 1.5 T can achieve the same clinical accuracy as a pelvic phase array
coil at 3.0 T, although ADC values can differ [28]. Nevertheless, pelvic
phase-array coils are greatly advantageous regarding patient comfort.
Also, the ROI delineation methodology is likely to influence ADC
estimates. Some authors use T2-w images for lesion demarcation, others
the b = 0 s/mm2 or DW images with higher b-values [8,10,11,13,23].
Our methodology for ROI demarcation was different from that used by
Peng et al. [10]; they used T2-w images and copied the ROI to the DW
images whereas we drew the ROI at b = 2000 s/mm2 and propagated
them to the other DW images. Since we included only the most re-
stricted lesion area, likely to represent the most malignant part of the
tumor, this is likely to explain the lower ADC values obtained. How-
ever, other factors could have contributed to the ADC differences found
between studies, namely variations in glandular and stromal structure,
differences in DWI protocols and patient population [29].
In our study, the prostate anatomy was divided into PZ and CG. The
term CG is used in the literature to represent the aggregation of the
‘transitional zone’ and the ‘central zone’. Since in prostate MRI the se-
paration between these zones is difficult, the term CG can be adopted to
avoid erroneous identification of lesion localization [29].
Our study has some limitations. Firstly, lesion ROI may not have
accurately reflected histological tumor outline. Also, we have to con-
sider that mean ADC values in PCa may have been overestimated. Some
patients underwent MRI after TRUS biopsy, which could have altered
the ADC values due to the presence of residual hemorrhagic compo-
nents. Although, we did not control the time between biopsy and MRI,
during image analysis we were alert to avoid areas of hemorrhage on
T1-w and T2-w images. Kim et al. reported that the influence of blood
on ADC measurements could be ignored [30]. We used the mono-
Table 3
ADC values for PCa and normal tissue globally and by region for the b-value combinations with AUC> 95%, and corresponding p-values.
b-values (s/mm2) PCa ADC (×10−3 mm2/s) Healthy tissue ADC (×10−3 mm2/s) p-value⁎
Global/PZ/CG
Global PZ CG Global PZ CG
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
50,800 1.02 ± 0.22 1.04 ± 0.22 0.95 ± 0.20 1.52 ± 0.24 1.54 ± 0.24 1.41 ± 0.21 p < 0.001/p < 0.001/p < 0.001
150,800 0.96 ± 0.21 0.98 ± 0.21 0.89 ± 0.21 1.47 ± 0.24 1.48 ± 0.24 1.36 ± 0.21 p < 0.001/p < 0.001/p < 0.001
50,1100 0.93 ± 0.19 0.94 ± 0.19 0.86 ± 0.15 1.38 ± 0.20 1.39 ± 0.20 1.28 ± 0.18 p < 0.001/p < 0.001/p < 0.001
0,1400 0.91 ± 0.18 0.92 ± 0.19 0.88 ± 0.12 1.35 ± 0.19 1.36 ± 0.19 1.24 ± 0.17 p < 0.001/p < 0.001/p < 0.001
50,1400 0.84 ± 0.17 0.85 ± 0.18 0.81 ± 0.13 1.26 ± 0.19 1.27 ± 0.19 1.16 ± 0.17 p < 0.001/p < 0.001/p < 0.001
100,1400 0.83 ± 0.17 0.84 ± 0.17 0.79 ± 0.13 1.24 ± 0.19 1.25 ± 0.19 1.14 ± 0.17 p < 0.001/p < 0.001/p < 0.001
150,1400 0.80 ± 0.17 0.81 ± 0.17 0.77 ± 0.13 1.21 ± 0.19 1.22 ± 0.19 1.12 ± 0.17 p < 0.001/p < 0.001/p < 0.001
0,1700 0.82 ± 0.15 0.83 ± 0.17 0.80 ± 0.10 1.18 ± 0.17 1.20 ± 0.17 1.05 ± 0.14 p < 0.001/p < 0.001/p < 0.001
50,1700 0.77 ± 0.15 0.77 ± 0.16 0.73 ± 0.12 1.12 ± 0.17 1.13 ± 0.17 1.05 ± 0.14 p < 0.001/p < 0.001/p < 0.001
100,1700 0.75 ± 0.15 0.76 ± 0.15 0.72 ± 0.12 1.10 ± 0.17 1.11 ± 0.17 1.03 ± 0.13 p < 0.001/p < 0.001/p < 0.001
0,2000 0.75 ± 0.13 0.75 ± 0.14 0.71 ± 0.08 1.07 ± 0.13 1.08 ± 0.13 1.03 ± 0.12 p < 0.001/p < 0.001/p < 0.001
50,2000 0.69 ± 0.13 0.70 ± 0.14 0.65 ± 0.10 1.01 ± 0.14 1.02 ± 0.14 0.97 ± 0.12 p < 0.001/p < 0.001/p < 0.001
100,2000 0.68 ± 0.13 0.69 ± 0.13 0.64 ± 0.10 0.99 ± 0.13 0.99 ± 0.13 0.95 ± 0.12 p < 0.001/p < 0.001/p < 0.001
150,2000 0.66 ± 0.12 0.67 ± 0.13 0.62 ± 0.10 0.97 ± 0.14 0.97 ± 0.14 0.93 ± 0.11 p < 0.001/p < 0.001/p < 0.001
200,2000 0.64 ± 0.12 0.65 ± 0.13 0.60 ± 0.10 0.94 ± 0.14 0.94 ± 0.14 0.91 ± 0.11 p < 0.001/p < 0.001/p < 0.001
ADC apparent diffusion coefficient; AUC area under the curve; SD standard deviation; PZ peripheral zone; CG Central Gland.
⁎ p-value differences in mean ADC values between PCa and healthy tissue globally and by region.
exponential model since it is widely implemented but several papers
highlight the importance of employing bi-exponential, kurtosis or other
more complex models for studying PCa [31,32]. Furthermore, our
sample was small, especially the number of included malignant CG
lesions, making the ADC values potentially less representative. Fur-
thermore, we had to exclude 19 patients from the study, since no le-
sions were detected in the MP-MRI analysis. However, it is well known
that MP-MRI does not have a 100% negative predictive value, espe-
cially in lesions classified with GS < 7 and smaller than 0.5 cm3 [33].
In any case, only 7 of those patients were diagnosed with PCa within
6 months of scanning. The relatively large slice thickness (6 mm) could
have limited detectability; partial volume effects could also potentially
explain why only one lesion was detected per patient while PCa is ty-
pically multifocal.
To our knowledge this is the first paper that performed ADC analysis
in PCa at 3.0 T, using a large combination of b-value pairs, with b-
values higher than b = 1000 s/mm2 and several minimum b-values
higher than b = 0 s/mm2.
Conclusion.
Although several b-value pairs presented statistically comparable
AUC, the b-value combination with highest AUC was b = 50, 2000 s/
mm2 with a sensitivity, specificity and accuracy of 95.5%, 93.2% and
94.4%, respectively. Future prostate cancer studies should validate this
combination by investigating ADC correlation with the GS.
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